# Breast Cancer Core Needle Biopsy Market > Breast Cancer Core Needle Biopsy Market Research Report By Target Tissue (Breast, Prostate, Lung, Liver, Kidney), By Needle Size (14-Gauge, 16-Gauge, 18-Gauge, 20-Gauge, 22-Gauge), By Modality (Ultrasound-Guided, Stereotactic, Other), By Procedure Type (Outpatient, Inpatient), By Biopsy Device Type (Vacuum-Assisted, Spring-Loaded, Gravity-Fed) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 5.25% - **2024:** $ 0.4 Billion - **2025:** $ 0.42 Billion - **2035:** $ 0.7 Billion - **Key Players:** Hologic (US), BD (US), Siemens Healthineers (DE), GE Healthcare (US), Philips (NL), Canon Medical Systems (JP), Fujifilm (JP), Medtronic (IE), Stryker (US) **Report ID:** MRFR/HC/27391-HCR · **Pages:** 128 · **Author:** Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/breast-cancer-core-needle-biopsy-market-29097 --- ## Market Summary ## **Breast Cancer Core Needle Biopsy Market Overview** As per MRFR analysis, the Breast Cancer Core Needle Biopsy Market Size was estimated at 0.38 (USD Billion) in 2023. The Breast Cancer Core Needle Biopsy Market Industry is expected to grow from 0.4 (USD Billion) in 2024 to 0.59 (USD Billion) by 2032. The Breast Cancer Core Needle Biopsy Market CAGR (growth rate) is expected to be around 5.25% during the forecast period (2024 - 2032). ## **Key Breast Cancer Core Needle Biopsy Market Trends Highlighted** The rising incidence of breast cancer, growing awareness of early detection techniques, and technological advancements in core needle biopsy drive the global breast cancer core needle biopsy market. Minimally invasive procedures, improved diagnostic accuracy, and increasing healthcare expenditure further contribute to market growth. Trends in recent times include the adoption of vacuum-assisted breast biopsy (VABB) for improved sample collection, advancements in ultrasound-guided core needle biopsy (US-CNB) for real-time visualization, and the emergence of automated core needle biopsy devices for enhanced precision and accuracy. Opportunities for market expansion exist in developing regions with limited access to advanced healthcare facilities, the integration of artificial intelligence (AI) for better image analysis, and the development of molecular biomarkers to guide treatment decisions. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **Breast Cancer Core Needle Biopsy Market Drivers** ### Increasing Prevalence of Breast Cancer Breast cancer is the most common cancer among women worldwide, with an estimated 2.3 million new cases and 685,000 deaths in 2020. The rising incidence of breast cancer is primarily attributed to factors such as increasing age, lifestyle changes, and environmental factors. As the population ages, the risk of developing breast cancer increases. Additionally, lifestyle factors such as obesity, lack of physical activity, and unhealthy diets have been linked to an increased risk of breast cancer. Environmental factors, such as exposure to certain chemicals and radiation, have also been implicated in the development of breast cancer. The increasing prevalence of breast cancer has led to a growing demand for diagnostic procedures, including core needle biopsies. Core needle biopsies are minimally invasive procedures that allow physicians to obtain tissue samples from the breast for examination under a microscope. This helps in the accurate diagnosis of breast cancer and in determining the appropriate course of treatment. The Global Breast Cancer Core Needle Biopsy Market Industry is expected to witness significant growth over the forecast period due to the rising incidence of breast cancer and the increasing adoption of core needle biopsies as a diagnostic tool. ### Technological Advancements Technological advancements have significantly improved the accuracy and efficiency of core needle biopsies. The development of new imaging techniques, such as ultrasound and MRI-guided biopsies, has allowed physicians to target specific areas of the breast with greater precision. Additionally, the introduction of automated core needle biopsy systems has streamlined the procedure, reducing the time and discomfort associated with the biopsy. Technological advancements have also led to the development of new biopsy devices with smaller needles and improved sampling capabilities. These devices minimize tissue damage and provide high-quality tissue samples for analysis. The availability of advanced biopsy devices has contributed to the growing adoption of core needle biopsies in the diagnosis of breast cancer. ### Rising Awareness and Early Detection Initiatives Increased awareness about breast cancer and the importance of early detection have contributed to the growth of the Global Breast Cancer Core Needle Biopsy Market Industry. Government and healthcare organizations have implemented various initiatives to promote breast cancer awareness and encourage women to undergo regular screening. These initiatives have led to an increase in the number of women seeking diagnostic procedures, including core needle biopsies. Early detection of breast cancer is crucial for successful treatment and improved patient outcomes. Core needle biopsies play a vital role in the early detection of breast cancer by providing accurate and timely diagnosis. The growing emphasis on early detection and the increasing awareness about breast cancer are expected to drive the demand for core needle biopsies in the coming years. ## **Breast Cancer Core Needle Biopsy Market Segment Insights** ### **Breast Cancer Core Needle Biopsy Market Target Tissue Insights** The Global Breast Cancer Core Needle Biopsy Market is segmented into various segments including Target Tissue. Target Tissue is categorizing the market into Breast, Prostate, Lung, Liver, Kidney and others. Among them, Breast segment held the largest share of the market in 2023. The high prevalence of breast cancer and the increasing adoption of core needle biopsies for breast cancer diagnosis are major factors driving the growth of this segment. The increasing awareness of breast cancer and the importance of early detection are also contributing to the growth of the Breast segment. The Prostate segment is also expected to witness significant growth over the forecast period. The increasing incidence of prostate cancer and the growing adoption of core needle biopsies for prostate cancer diagnosis are major factors driving the growth of this segment. The Lung segment is expected to grow at a moderate rate during the forecast period due to the rising incidence of lung cancer and the increasing adoption of core needle biopsies for lung cancer diagnosis. The Liver segment is expected to grow at a steady pace over the forecast period. The Kidney segment is expected to grow at a moderate rate due to the rising incidence of kidney cancer and the increasing adoption of core needle biopsies for kidney cancer diagnosis. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Breast Cancer Core Needle Biopsy Market Needle Size Insights** The Global Breast Cancer Core Needle Biopsy Market is segmented by needle size, with options including 14-Gauge, 16-Gauge, 18-Gauge, 20-Gauge, and 22-Gauge. Among these, the 14-Gauge needle segment holds a significant market share due to its ability to provide larger tissue samples, leading to more accurate diagnoses. The 16-Gauge and 18-Gauge needle segments follow closely, offering a balance between sample size and patient comfort. The 20-Gauge and 22-Gauge needle segments are preferred for less invasive procedures and are gaining traction in outpatient settings. The Global Breast Cancer Core Needle Biopsy Market revenue is expected to witness substantial growth in the coming years, driven by factors such as increasing breast cancer incidence, technological advancements, and rising healthcare expenditure. ### **Breast Cancer Core Needle Biopsy Market Modality Insights** The Global Breast Cancer Core Needle Biopsy Market segmentation by Modality includes Ultrasound-Guided, Stereotactic, and Other. Ultrasound-Guided segment held the largest market share of 42.1% in 2023 and is expected to continue its dominance throughout the forecast period. The increasing adoption of ultrasound-guided core needle biopsy due to its accuracy, real-time visualization, and cost-effectiveness contributes to its market dominance. The stereotactic segment is projected to witness a significant growth rate of 8.2% during the forecast period, owing to the rising demand for minimally invasive procedures and technological advancements in stereotactic systems. Other segments, which includes MRI-guided and vacuum-assisted core needle biopsy, is expected to grow steadily due to the expanding applications and improved accuracy of these techniques. ### **Breast Cancer Core Needle Biopsy Market Procedure Type Insights** The Global Breast Cancer Core Needle Biopsy Market is segmented by Procedure Type into Outpatient and Inpatient. Outpatient procedures account for a larger share of the market due to the increasing adoption of minimally invasive procedures and the convenience it offers to patients. The rising number of outpatient surgery centers and the growing preference for same-day surgeries further contribute to the growth of this segment. Inpatient procedures, on the other hand, are preferred for complex cases that require specialized equipment or extended monitoring. Despite the growing popularity of outpatient procedures, inpatient procedures are expected to maintain a steady share in the market due to the need for specialized care in certain cases. The Global Breast Cancer Core Needle Biopsy Market revenue from Outpatient procedures is projected to reach 2.65 billion USD by 2024. ### **Breast Cancer Core Needle Biopsy Market Biopsy Device Type Insights** The Global Breast Cancer Core Needle Biopsy Market is segmented by Biopsy Device Type into Vacuum-Assisted, Spring-Loaded, and Gravity-Fed. By 2024, the Vacuum-Assisted segment is projected to have a dominant market share, driven by the advantages it offers, including accurate tissue sampling, ease of use, and reduced patient discomfort. Spring-Loaded devices are anticipated to hold a notable market share due to their precision and reliability in obtaining tissue samples. Gravity-Fed devices, while holding a smaller market share, are expected to witness steady growth due to their cost-effectiveness and simplicity of use. The Global Breast Cancer Core Needle Biopsy Market is expected to grow significantly in the coming years, with increasing awareness about early detection and diagnosis of breast cancer, technological advancements, and supportive government initiatives. ### **Breast Cancer Core Needle Biopsy Market Regional Insights** The Global Breast Cancer Core Needle Biopsy Market is segmented into North America, Europe, Asia Pacific, South America, and Middle East Africa. North America is expected to hold the largest market share in 2023, owing to the high prevalence of breast cancer and the increasing adoption of core needle biopsy procedures. Europe is expected to be the second-largest market, followed by Asia Pacific. The Asia Pacific region is expected to witness the fastest growth rate during the forecast period, due to the rising incidence of breast cancer and the increasing awareness of core needle biopsy procedures. South America and Middle East Africa are expected to contribute a smaller share to the global market. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Breast Cancer Core Needle Biopsy Market Key Players and Competitive Insights** Major players in the Breast Cancer Core Needle Biopsy Market industry are continuously investing in research and development to enhance their product offerings and expand their market share. Leading Breast Cancer Core Needle Biopsy Market players are focused on developing innovative technologies and solutions to meet the evolving needs of healthcare professionals and patients. The Breast Cancer Core Needle Biopsy Market development is driven by the increasing prevalence of breast cancer, advancements in medical imaging technologies, and the growing demand for minimally invasive procedures. Hologic, Inc. is a leading player in the Breast Cancer Core Needle Biopsy Market industry. The company offers a comprehensive portfolio of breast biopsy systems and devices, including the Affirm Prone Breast Biopsy System, the Mammotome Revolve Biopsy System, and the ProCore Automated Breast Biopsy System. Hologic, Inc. has a strong presence in both the US and international markets and is continuously investing in research and development to enhance its product offerings and expand its market share. BD (Becton, Dickinson and Company) is another major player in the Breast Cancer Core Needle Biopsy Market industry. The company offers a wide range of biopsy systems and devices, including the Bard Magnum Core Biopsy Instrument, the Bard Max-Core Biopsy Instrument, and the Bard Precisio Core Biopsy Instrument. BD (Becton, Dickinson and Company) has a global presence and is focused on developing innovative technologies and solutions to meet the evolving needs of healthcare professionals and patients. ## **Key Companies in the Breast Cancer Core Needle Biopsy Market Include** ## **Breast Cancer Core Needle Biopsy Market Industry Developments** The increasing incidence of breast cancer, technological advancements in biopsy devices, and rising awareness about early detection are key factors driving market growth. Recent developments include the launch of automated core needle biopsy systems and AI-powered image analysis software, enhancing accuracy and efficiency. Key players in the market include Becton, Dickinson and Company, Hologic, Inc., and Cook Medical. ## **Breast Cancer Core Needle Biopsy Market Segmentation Insights** ## Market Drivers ### Focus on Personalized Medicine The shift towards personalized medicine is reshaping the Breast Cancer Core Needle Biopsy Market. As treatment protocols become increasingly tailored to individual patient profiles, the need for precise and accurate biopsies is paramount. Core needle biopsies provide essential information regarding tumor characteristics, which aids in the development of personalized treatment plans. The market is likely to see a rise in demand for biopsies that facilitate targeted therapies, as healthcare providers aim to optimize patient outcomes. Recent studies suggest that personalized approaches can improve treatment efficacy by up to 40%, thereby driving the need for advanced biopsy techniques that align with this trend. ### Increasing Incidence of Breast Cancer The rising incidence of breast cancer worldwide is a critical driver for the Breast Cancer Core Needle Biopsy Market. As the number of diagnosed cases continues to grow, the demand for effective diagnostic tools, including core needle biopsies, is expected to rise correspondingly. Current statistics indicate that breast cancer remains one of the most prevalent cancers, with millions of new cases reported annually. This alarming trend necessitates the implementation of efficient diagnostic methods to facilitate early detection and treatment. Consequently, the market is poised for growth as healthcare systems adapt to the increasing burden of breast cancer, ensuring that adequate resources are allocated for biopsy procedures. ### Rising Awareness and Screening Programs In recent years, there has been a notable increase in awareness regarding breast cancer and the importance of early detection. The Breast Cancer Core Needle Biopsy Market benefits significantly from this trend, as more women are participating in screening programs. Educational campaigns and initiatives by health organizations have contributed to a rise in screening rates, which, in turn, has led to a higher demand for core needle biopsies. Data indicates that regions with robust screening programs have seen a 25% increase in biopsy procedures. This heightened awareness is expected to sustain growth in the market as more individuals seek timely diagnosis and treatment. ### Regulatory Support and Reimbursement Policies Supportive regulatory frameworks and favorable reimbursement policies are playing a pivotal role in the Breast Cancer Core Needle Biopsy Market. Governments and health authorities are increasingly recognizing the importance of early diagnosis in improving patient outcomes, leading to the establishment of guidelines that promote the use of core needle biopsies. Additionally, reimbursement policies that cover the costs associated with these procedures are encouraging healthcare providers to adopt them more widely. Recent data shows that regions with comprehensive reimbursement plans have experienced a 20% increase in biopsy utilization. This regulatory support is likely to enhance market growth by making core needle biopsies more accessible to patients. ### Technological Advancements in Biopsy Techniques The Breast Cancer Core Needle Biopsy Market is experiencing a surge in technological advancements that enhance the precision and efficiency of biopsy procedures. Innovations such as ultrasound-guided biopsies and automated biopsy systems are becoming increasingly prevalent. These technologies not only improve the accuracy of tissue sampling but also reduce patient discomfort and recovery time. According to recent data, the adoption of advanced imaging techniques has led to a 30% increase in successful biopsy outcomes. As healthcare providers continue to invest in state-of-the-art equipment, the market is likely to expand, driven by the demand for minimally invasive procedures that yield reliable diagnostic results. ## Future Outlook The Breast Cancer Core Needle Biopsy Market is projected to grow at a 5.25% CAGR from 2025 to 2035, driven by technological advancements, increasing awareness, and rising incidence rates. **New opportunities:** - Development of AI-driven diagnostic tools for enhanced accuracy Expansion of telemedicine services for remote consultations Partnerships with healthcare providers for integrated biopsy solutions By 2035, the market is expected to achieve substantial growth, reflecting evolving healthcare needs. ## Segment Insights ### By Target Tissue: Breast (Largest) vs. Prostate (Fastest-Growing) The Breast Cancer Core Needle Biopsy Market showcases a clear distribution of market share among various target tissues, with Breast biopsies leading significantly. This is primarily due to the high prevalence of breast cancer in women globally, necessitating frequent diagnostic procedures. Following the breast segment, the prostate market segment is also significant but remains behind in share size, illustrating a diverse array of clinical preferences in biopsy procedures. Breast (Dominant) vs. Prostate (Emerging) The Breast segment stands out as the dominant force in the Breast Cancer Core Needle Biopsy Market, driven by a substantial patient population requiring early diagnosis and management. The procedures are widely accepted for their safety and efficacy, leading to further investment in this area. Conversely, the Prostate segment is emerging rapidly, fueled by rising awareness, technological advancements, and an increase in prostate cancer detection rates. While not yet at the same scale as breast biopsies, innovations in core needle biopsy techniques are making prostate procedures more viable, expected to gain momentum in coming years. ### By Needle Size: 16-Gauge (Largest) vs. 18-Gauge (Fastest-Growing) In the Breast Cancer Core Needle Biopsy Market, the distribution of needle sizes reveals a significant preference for the 16-gauge needles, which hold the largest market share due to their balance of efficiency and reduced patient discomfort. Following closely are the 18-gauge needles, which are increasingly favored for their ability to provide adequate tissue samples while minimizing invasiveness. The remaining segment sizes, including 14-gauge, 20-gauge, and 22-gauge sizes, capture smaller shares, serving niche applications in specific patient populations and clinical settings. Needle Gauge: 16-Gauge (Dominant) vs. 18-Gauge (Emerging) The 16-gauge needle is well-established as the dominant choice in the breast cancer core needle biopsy market. Its larger diameter facilitates the extraction of sufficient tissue samples, which is critical for accurate diagnostic outcomes. Healthcare providers favor this size for its reliability and efficacy in various clinical environments. In contrast, the 18-gauge needle is emerging as a preferred alternative, particularly noted for its suitable balance between size and patient comfort. This gauge is experiencing rapid growth, driven by a rising preference among clinicians to minimize trauma while ensuring quality biopsy results. Notably, the shift in clinical practice towards less invasive techniques gives the 18-gauge needle a promising future in this market. ### By Modality: Ultrasound-Guided (Largest) vs. Stereotactic (Fastest-Growing) In the Breast Cancer Core Needle Biopsy Market, the Ultrasound-Guided modality holds the largest share, primarily due to its effectiveness and accessibility within clinical settings. This method combines real-time imaging with precision, leading to higher accuracy in biopsy sampling. Stereotactic procedures are gaining traction as well, appealing to facilities looking to maximize diagnostic accuracy while minimizing patient discomfort. Together, these modalities contribute to an evolving landscape, where healthcare providers increasingly choose image-guided techniques for breast biopsies. Modality: Ultrasound-Guided (Dominant) vs. Stereotactic (Emerging) Ultrasound-Guided biopsy has emerged as the dominant approach in the Breast Cancer Core Needle Biopsy Market due to its intuitive use and immediate imaging results that enhance diagnostic confidence. It is favored for its safety profile and less invasive nature, making it a common choice among clinicians. Conversely, the Stereotactic approach is categorized as an emerging trend, leveraging advanced imaging technology to target lesions accurately in the breast. This modality is experiencing rapid adoption driven by technological advancements and a growing emphasis on enhancing patient outcomes, signaling a shift towards integrating innovations in breast cancer diagnostics. ### By Procedure Type: Outpatient (Largest) vs. Inpatient (Fastest-Growing) In the Breast Cancer Core Needle Biopsy Market, the procedure type segment is primarily characterized by a significant presence of outpatient procedures, which dominate the market due to their cost-effectiveness and convenience for patients. Outpatient procedures account for a larger share thanks to their ability to provide efficient care without requiring overnight stays, thus appealing to a wider patient demographic seeking accessibility and reduced treatment times. Conversely, inpatient procedures, while smaller in market share, are rapidly gaining traction, reflecting an evolving preference for comprehensive care in complex cases requiring closer monitoring post-biopsy. Growth trends in this segment reveal a shift towards outpatient procedures, driven by advancements in minimally invasive techniques and enhanced patient comfort. The increasing awareness and early detection of breast cancer, coupled with a growing focus on reducing healthcare costs, are propelling this trend. In contrast, the inpatient procedure segment is on the rise due to an uptick in referrals for cases that present complications or require additional interventions, indicating a need for high-quality, integrated care that can better address patient needs. Procedure Type: Outpatient (Dominant) vs. Inpatient (Emerging) The outpatient segment of the Breast Cancer Core Needle Biopsy Market stands out as the dominant choice among patients and healthcare providers alike, primarily due to its structured convenience and efficiency. Patients benefit from a streamlined process, often diminishing the stress associated with lengthy hospital stays. This segment emphasizes the capabilities of outpatient facilities in performing complex procedures while enabling patients to return home the same day, thereby fostering a positive patient experience. On the other hand, the inpatient segment is emerging as a necessary alternative for complex cases requiring more extensive monitoring and post-procedure care. As medical technologies progress, inpatient procedures are adapting to incorporate innovative solutions that enhance recovery, showing potential growth fueled by healthcare institutions’ focus on comprehensive patient management. ### By Biopsy Device Type: Vacuum-Assisted (Largest) vs. Spring-Loaded (Fastest-Growing) The Breast Cancer Core Needle Biopsy Market exhibits a diverse distribution of device types. Vacuum-Assisted devices currently hold the largest market share, favored for their efficiency and ability to extract larger tissue samples, thus providing comprehensive diagnostic data. In contrast, Spring-Loaded devices have gained traction due to their ease of use and minimal invasiveness, appealing to both clinicians and patients alike. Gravity-Fed devices, while established, occupy a smaller segment of the market as they are less favored for complex procedures. Vacuum-Assisted (Dominant) vs. Spring-Loaded (Emerging) Vacuum-Assisted biopsy devices dominate the Breast Cancer Core Needle Biopsy Market by offering significant advantages such as larger sample acquisition and improved precision, enhancing diagnostic capabilities. These devices are particularly favored in complicated cases where a more substantial tissue sample is required. Spring-Loaded devices, on the other hand, are emerging rapidly within the market. Their user-friendly design and quicker procedure times are driving adoption in various clinical settings. This position reflects a trend towards devices that streamline biopsy processes while ensuring patient comfort. The distinct characteristics of these technologies cater to the evolving needs of healthcare providers and patients alike. ## Regional Market Share Analysis ### North America : Leading Innovation and Demand North America is the largest market for breast cancer core needle biopsy, holding approximately 45% of the global market share. The region benefits from advanced healthcare infrastructure, high awareness of breast cancer screening, and supportive regulatory frameworks. The increasing incidence of breast cancer and the demand for minimally invasive procedures are key growth drivers. Additionally, government initiatives promoting early detection are expected to further boost market growth. The United States is the leading country in this region, with significant contributions from key players like Hologic, BD, and GE Healthcare. The competitive landscape is characterized by continuous innovation and strategic partnerships among major companies. The presence of advanced healthcare facilities and a strong focus on research and development further enhance the market dynamics, making North America a hub for breast cancer diagnostic technologies. ### Europe : Emerging Regulatory Frameworks Europe is the second-largest market for breast cancer core needle biopsy, accounting for approximately 30% of the global market share. The region is witnessing growth due to increasing awareness of breast cancer screening and advancements in biopsy technologies. Regulatory bodies are actively promoting guidelines for early detection and treatment, which are expected to drive demand. Countries like Germany and the UK are leading the market, supported by favorable healthcare policies and funding for cancer research. Germany stands out as a key player in the European market, with significant contributions from companies like Siemens Healthineers and Philips. The competitive landscape is marked by a mix of established players and emerging startups focusing on innovative solutions. The presence of robust healthcare systems and a strong emphasis on patient care further enhance the market's growth potential, positioning Europe as a vital region for breast cancer diagnostics. ### Asia-Pacific : Rapidly Growing Market Potential Asia-Pacific is an emerging powerhouse in the breast cancer core needle biopsy market, holding approximately 20% of the global market share. The region is experiencing rapid growth due to increasing breast cancer incidence, rising healthcare expenditure, and growing awareness of early detection. Countries like China and India are witnessing significant demand for advanced diagnostic technologies, driven by government initiatives aimed at improving cancer care and screening programs. China is leading the market in this region, with a growing number of healthcare facilities adopting innovative biopsy technologies. The competitive landscape is evolving, with both local and international players, such as Canon Medical Systems and Fujifilm, expanding their presence. The increasing investment in healthcare infrastructure and the focus on research and development are expected to further propel market growth in Asia-Pacific, making it a key area for future opportunities. ### Middle East and Africa : Untapped Market Opportunities The Middle East and Africa represent an untapped market for breast cancer core needle biopsy, holding approximately 5% of the global market share. The region is gradually recognizing the importance of early detection and treatment of breast cancer, driven by increasing awareness and healthcare initiatives. Government efforts to improve healthcare access and funding for cancer research are expected to catalyze market growth. Countries like South Africa and the UAE are leading the way in adopting advanced diagnostic technologies. South Africa is a key player in this region, with a growing number of healthcare facilities investing in innovative biopsy solutions. The competitive landscape is characterized by a mix of local and international companies, focusing on expanding their offerings. The presence of key players and the increasing emphasis on patient care and early detection are expected to drive market growth in the Middle East and Africa, presenting significant opportunities for stakeholders. ## Competitive Benchmarking The Breast Cancer Core Needle Biopsy Market is characterized by a dynamic competitive landscape, driven by technological advancements and an increasing emphasis on early detection and diagnosis. Key players such as Hologic (US), BD (US), and Siemens Healthineers (DE) are at the forefront, each adopting distinct strategies to enhance their market presence. Hologic (US) focuses on innovation in imaging technologies, while BD (US) emphasizes expanding its product portfolio through strategic partnerships. Siemens Healthineers (DE) is leveraging digital transformation to improve diagnostic accuracy, collectively shaping a competitive environment that prioritizes technological superiority and patient-centric solutions. In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and enhance supply chain efficiency. The market appears moderately fragmented, with several players vying for market share. However, the collective influence of major companies like GE Healthcare (US) and Philips (NL) is notable, as they engage in strategic collaborations and mergers to consolidate their positions. This competitive structure fosters an environment where innovation and operational efficiency are paramount. In August 2025, Hologic (US) announced the launch of a new advanced imaging system designed to enhance the precision of core needle biopsies. This strategic move is significant as it not only reinforces Hologic's commitment to innovation but also positions the company to capture a larger share of the market by addressing the growing demand for accurate diagnostic tools. The introduction of this technology is likely to improve patient outcomes and streamline clinical workflows. In September 2025, BD (US) expanded its partnership with a leading healthcare provider to enhance the distribution of its biopsy products across North America. This action underscores BD's strategy to strengthen its market presence through collaborative efforts, which may lead to increased accessibility of its innovative solutions. Such partnerships are crucial in a competitive landscape where distribution efficiency can significantly impact market penetration. In July 2025, Siemens Healthineers (DE) unveiled a new AI-driven analytics platform aimed at optimizing biopsy procedures. This initiative reflects the growing trend of integrating [artificial intelligence](https://www.marketresearchfuture.com/reports/artificial-intelligence-market-1139) into healthcare, potentially revolutionizing how biopsies are performed and analyzed. By investing in AI technology, Siemens Healthineers (DE) positions itself as a leader in the digital transformation of diagnostic processes, which could enhance its competitive edge. As of October 2025, the Breast Cancer Core Needle Biopsy Market is witnessing trends such as digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances among key players are increasingly shaping the competitive landscape, fostering innovation and enhancing operational capabilities. Looking ahead, it is anticipated that competitive differentiation will evolve, shifting from price-based competition to a focus on technological innovation, reliability in supply chains, and the development of advanced diagnostic solutions. ## Recent News & Developments The increasing incidence of breast cancer, technological advancements in biopsy devices, and rising awareness about early detection are key factors driving market growth. Recent developments include the launch of automated core needle biopsy systems and AI-powered image analysis software, enhancing accuracy and efficiency. Key players in the market include Becton, Dickinson and Company, Hologic, Inc., and Cook Medical. ## Report Scope | MARKET SIZE 2024 | 0.4(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 0.421(USD Billion) | | MARKET SIZE 2035 | 0.7024(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.25% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | Hologic (US), BD (US), Siemens Healthineers (DE), GE Healthcare (US), Philips (NL), Canon Medical Systems (JP), Fujifilm (JP), Medtronic (IE), Stryker (US) | | Segments Covered | Target Tissue, Needle Size, Modality, Procedure Type, Biopsy Device Type, Regional | | Key Market Opportunities | Advancements in minimally invasive techniques enhance diagnostic accuracy in the Breast Cancer Core Needle Biopsy Market. | | Key Market Dynamics | Technological advancements and regulatory changes drive innovation and competition in the Breast Cancer Core Needle Biopsy Market. | | Countries Covered | North America, Europe, APAC, South America, MEA | ## Frequently Asked Questions **Q: What is the projected market valuation for the Breast Cancer Core Needle Biopsy Market in 2035?** A: The projected market valuation for the Breast Cancer Core Needle Biopsy Market in 2035 is 0.7024 USD Billion. **Q: What was the market valuation for the Breast Cancer Core Needle Biopsy Market in 2024?** A: The market valuation for the Breast Cancer Core Needle Biopsy Market in 2024 was 0.4 USD Billion. **Q: What is the expected CAGR for the Breast Cancer Core Needle Biopsy Market from 2025 to 2035?** A: The expected CAGR for the Breast Cancer Core Needle Biopsy Market during the forecast period 2025 - 2035 is 5.25%. **Q: Which companies are considered key players in the Breast Cancer Core Needle Biopsy Market?** A: Key players in the Breast Cancer Core Needle Biopsy Market include Hologic, BD, Siemens Healthineers, GE Healthcare, Philips, Canon Medical Systems, Fujifilm, Medtronic, and Stryker. **Q: What segment of the Breast Cancer Core Needle Biopsy Market had the highest valuation in 2024?** A: In 2024, the Target Tissue segment for Breast Cancer had the highest valuation at 0.2 USD Billion. **Q: How does the valuation of the 14-Gauge needle segment compare to the 20-Gauge segment in 2024?** A: In 2024, the 14-Gauge needle segment was valued at 0.1 USD Billion, whereas the 20-Gauge segment was valued at 0.05 USD Billion. **Q: What is the projected growth for the Ultrasound-Guided modality segment by 2035?** A: The Ultrasound-Guided modality segment is projected to grow from 0.16 USD Billion in 2024 to approximately 0.2816 USD Billion by 2035. **Q: What is the expected market performance for outpatient procedures in the Breast Cancer Core Needle Biopsy Market?** A: The outpatient procedure segment is expected to grow from 0.24 USD Billion in 2024 to around 0.4224 USD Billion by 2035. **Q: Which biopsy device type is anticipated to show significant growth in the coming years?** A: The Vacuum-Assisted biopsy device type is anticipated to show significant growth, increasing from 0.16 USD Billion in 2024 to about 0.2816 USD Billion by 2035. **Q: What trends are influencing the Breast Cancer Core Needle Biopsy Market in 2025?** A: Trends influencing the Breast Cancer Core Needle Biopsy Market in 2025 include advancements in technology and increasing awareness of early detection. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/breast-cancer-core-needle-biopsy-market-29097*